Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Inflammatory Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CCL5/RANTES drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CCL5/RANTES ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View CCL5 Products |
| Gene Delivery | CCL5 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View CCL5 Products |
| Benchmark Ab | Anti-CCL5 Recombinant Antibody Recombinant positive control. |
View CCL5 Products |
| Validator | CCL5 siRNA Set For knockdown verification. |
View CCL5 Products |
| Related Target A | CCR5 Primary GPCR receptor mediating CCL5-induced chemotaxis in immunosuppressive cells. |
View CCR5 Products |
| Related Target B | CCR1 Alternative receptor involved in inflammatory cell recruitment and metastasis bypass pathways. |
View CCR1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Oligomerization state control (aggregation interference) | Monomeric mutants (e.g., E26A) and wild-type proteins strictly verified by SDS-PAGE and SEC-MALS for aggregation control. |
| Receptor selectivity profiling (CCR5 vs CCR1/CCR3) | High-titer Lentiviral particles available for stable cell line generation to support calcium flux and chemotaxis assays. |
| Lack of Clinical Benchmarks | Sequence-verified biosimilar recombinant antibodies included to calibrate screening assay sensitivity. |
| Epitope cross-reactivity verification | Human, Mouse, and Cynomolgus ortholog proteins available with >95% purity and verified native glycosylation (HEK293 expressed). |
Live CCL5/RANTES R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CCL5/RANTES therapeutics is intensifying, with major players shifting focus from traditional systemic chemokine blockade to localized tumor microenvironment (TME) modulation. As first-generation CCR5 antagonists (such as Maraviroc) demonstrate clinical utility in colorectal cancer and NASH, the next wave of R&D is targeting the CCL5 ligand directly using monoclonal antibodies and bispecific formats to avoid systemic GPCR-related toxicities.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibodies (mAbs) | Biopharma Innovators | Solid Tumors (CRC, Breast Cancer), NASH | Ligand neutralization assay (Requires high-purity, low-endotoxin CCL5 protein) |
| Bispecifics (e.g., CCL5 x PD-L1) | Oncology-focused Biotechs | Cold Tumors, Immune Evasion | Dual-targeting validation (Requires stable CCR5-expressing cells via Lentivirus delivery) |
| Small Molecule Antagonists | Academic & Clinical Consortiums | Inflammatory Diseases, HIV-1 | Receptor binding competition (Requires sequence-verified WT vs Mutant CCL5 proteins) |